NCT05481463View on ClinicalTrials.gov

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 30, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

May 10, 2025

Conditions
Pancreatic Neoplasms
Interventions
DRUG

Surufatinib

surufatinib,250mg, qd, po, 28 days for a cycle

DRUG

TAS-102

TAS-102,35mg/m2, po, d1-5, d8-12, bid, 28 days for a cycle

Trial Locations (1)

510060

Cancer center of SunYat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER